이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Editas Medicine 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Gilmore O’Neill
최고 경영자
US$2.4m
총 보상
| CEO 급여 비율 | 26.8% |
| CEO 임기 | 2yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 1.3yrs |
| 이사회 평균 재임 기간 | 4.4yrs |
최근 관리 업데이트
Recent updates
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$166m |
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
보상 대 시장: Gilmore 의 총 보상 ($USD 2.39M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.46M ).
보상과 수익: Gilmore 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Gilmore O’Neill (60 yo)
2yrs
테뉴어
US$2,392,309
보상
Dr. Gilmore O’Neill, M. B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 2yrs | US$2.39m | 0.13% $ 499.1k | |
| CFO & Executive VP | 1.1yrs | US$2.69m | 0.028% $ 107.9k | |
| Executive VP & Chief Scientific Officer | less than a year | US$1.73m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 1.9yrs | US$1.14m | 0.041% $ 158.7k | |
| Co-Founder & Scientific Advisory Board Member | 11.4yrs | 데이터 없음 | 데이터 없음 | |
| Co-Founder & Scientific Advisory Board Member | 11.4yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief Technical & Quality Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Corporate Communications & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & General Counsel | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief People Officer | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief Commercial & Strategy Officer | less than a year | 데이터 없음 | 데이터 없음 |
1.3yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 관리: EDIT 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | no data | US$2.39m | 0.13% $ 499.1k | |
| Co-Founder & Scientific Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder & Scientific Advisory Board Member | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman of the Board | 2.8yrs | US$238.24k | 0% $ 0 | |
| Independent Director | 7.9yrs | US$208.06k | 0% $ 0 | |
| Independent Director | 7.1yrs | US$210.56k | 0.0024% $ 9.3k | |
| Independent Director | 6.3yrs | US$231.07k | 0.082% $ 316.2k | |
| Independent Director | 1.2yrs | US$264.88k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$213.06k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$215.06k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$205.56k | 0% $ 0 |
4.4yrs
평균 재임 기간
64.5yo
평균 연령
경험이 풍부한 이사회: EDIT 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.